Articles by Tyler Menichiello

  1. Improving AAV Purity Upstream With PCL Manufacturing 3/21/2024

    The downstream separation of AAV capsids affects end-product purity and has been identified as a key pain point of the industry. Ultragenyx’s Dennis Huang advises starting with higher-quality yields upstream.

  2. The Industry’s Positive Outlook For ADCs In 2024 2/26/2024

    Check out the results of DeciBio's Antibody-Drug Conjugates 2024 Industry Survey, which predict another bullish year for the growing modality.

  3. Addressing The GMP Skills Shortage With Virtual Reality 2/14/2024

    In the U.K., a professor at the University of Birmingham is using virtual reality (VR) to help address the growing biomanufacturing skills shortage  — using virtual reality (VR).

  4. Factors To Consider When Licensing An ADC Program 1/30/2024

    Elevation Oncology's CEO and CSO explain what made the company's lead ADC candidate, EO-3021, worth licensing from Chinese pharmaceutical company, CSPC.

  5. 2023 ADC Roundup: A Year Of Collaboration And Licensing Deals 1/3/2024

    Despite the continuation of a poor funding climate in biotech, 2023 was a big year for antibody-drug conjugates (ADCs). 

  6. RNA Vaccines: Just Scratching The Surface 12/28/2023

    RNA vaccines have shown promise in preventing infectious diseases and treating cancer, but clinical development varies markedly between the two. HDT Bio’s Dr. Berglund discusses this and how they can be improved.

  7. How Creative Licensing Can Improve Patient Access 11/16/2023

    Members of Caring Cross and UC Berkeley's Innovative Genomics Institute and Office of IP And Industry Research Alliances discuss the important role technology transfer offices (TTOs) play in improving ATMP accessibility. TTOs can accomplish this by designing "strings-attached" research and licensing deals upstream in product development.

  8. Targeting The Gut–Brain Axis With Live Biotherapeutic Products 9/8/2023

    Treating seizures with bacteria — Bloom Science's CEO, Dr. Christopher Reyes, explains how his company aims to leverage the gut–brain axis using live biotherapeutic products (LBP).

  9. ADC Advancements Allowing For Higher DAR 8/22/2023

    A high drug-antibody-ratio (DAR) used to mean higher off-target toxicity for ADCs. Now, thanks to improvements in linker technology and antibody targeting, higher DARs can allow for improved efficacy.

  10. How Linker Technology Is Driving ADC Development 8/4/2023

    If you’re still not excited about antibody drug conjugates (ADCs), “there’s an issue with you.” That’s the passionate, bullish sentiment (jokingly) held by Dr. Joe Daccache, project leader at DeciBio. Here, Daccache explains how innovations in linker technology are advancing the field of ADCs.